

12 February 2021

ASX ANNOUNCEMENT

American College of Cardiology Accepts SOZO HF Abstract

Brisbane, Australia – ImpediMed Limited (ASX:IPD), a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health is pleased to announce that an abstract evaluating the use of ImpediMed's SOZO® BIS technology in identifying heart failure (HF) patients at risk of hospital readmission at the time of discharge has been accepted for poster presentation at the American College of Cardiology (ACC) 70th Annual Scientific Session on 15-17 May 2021 in Atlanta, Georgia, USA.

The ACC Conference is "focusing on the latest science, innovation and practice-changing updates in care." To be awarded a poster presentation at this prestigious conference, focusing on innovation in cardiac care, is a tremendous opportunity for the company and is the perfect forum to introduce SOZO to Cardiologists from the US and around the world. The conference will be a tandem conference with both physical and virtual attendance. The poster results will be published online in the Journal of the American College of Cardiology Abstract Supplement prior to the ACC Annual Scientific Session.

The abstract, titled "Bioimpedance Spectroscopy Measurement of Ongoing Fluid Overload Post-Discharge from Hospitalization for Decompensated Heart Failure," analyses data collected during ImpediMed's Heart Failure Home Study using the SOZO Digital Health Platform. During the study, SOZO was used to measure patients' fluid status at home for 45 days following a heart failure-related hospital stay. In the abstract, HF-Dex™ was used to quantify fluid overload in patients between 48 and 72 hours post-discharge in patients who were readmitted to the hospital for heart failure compared to those patients who were not readmitted.

"Heart failure-related hospitalisations continue to be a challenge for medical professionals who lack effective tools to assess the degree of fluid overload prior to hospital discharge," explained Dr. Andrew Accardi, Emergency Medicine Physician at Scripps Health in San Diego, California and lead author of the poster. "New technologies like SOZO with HF-Dex have the potential to identify patients at high-risk for readmission prior to discharge and give healthcare professionals an opportunity to intervene with the goal of reducing readmissions," added Dr. Tom Heywood, Heart Failure Cardiologist at Scripps Health and poster co-author.

The SOZO fluid analysis for heart failure provides an objective measure of fluid overload in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented together with BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51% and is a potential marker for readmission.

"The ACC annual meeting is the leading scientific session for US cardiology and has global reach," commented Richard Carreon, Managing Director and CEO of ImpediMed. "Presenting data here lends important credibility to our technology and its potential to integrate into existing patient care pathways for the reduction of hospital readmissions. These results will support our commercialisation effort in heart failure, which is one of our three strategic focus areas."

The American College of Cardiology is the premier professional society for cardiology with more than 54,000 members. The mission of the College is to transform cardiovascular care and to improve heart health, with a vision where innovation and knowledge optimise cardiovascular care and outcomes. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor Relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

Media Contact:

Kyahn Williamson, WE Communications

T: +61 3 8866 1200

E: kwilliamson@we-worldwide.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>

About SOZO Fluid Analysis for Heart Failure

The SOZO fluid analysis for heart failure provides an objective measure of fluid overload in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented together with BIS-derived reference ranges for normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. When used as part of a clinical assessment of heart failure, SOZO helps differentiate between fluid and tissue-related weight changes to track response to medication changes and to provide a marker for readmission when HF-Dex is higher than 51%.

For more information, visit: <https://www.impedimed.com/healthcare/heart-failure/>

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only